PCVX's Quality Score rose 1 point on Mon, Nov 9, to 2.
Follow PCVX's trial news. Pro members can get an alert when Vaxcyte files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 5.7% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%.
| Holding it back | A $1.1B loss |
| Latest filing | 8-K, Nov 4 |
PCVX closed +30.7% that day on 12.5x normal volume.
After its last 4 reports it closed -1.9% on average, higher 2 of 4 times.
The company says its cash lasts into Mid-2028 (8-K, Nov 4, 2025).
SVP, Finance & CAO Elvia Cowan sold 3,000 shares on Nov 2, under a planned sale. 22 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Below Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
PCVX is #112 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 112 |
Share count against a year before: PCVX +6.2%, IMVT +20%, RLAY +18%, MRNA +2.8%.
Expected to report Tue Feb 23, after the close (in 106 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $1.99 a share, from $1.56.
“The increase was due primarily to higher development and product manufacturing costs associated with the Company's PCV programs, including manufacturing activities to support the potential future commercial launches and clinical trial expenses primarily related to the VAX-31 OPUS Phase 3 trials, as well as higher personnel expenses related to the growth in the number of R&D employees.”
PCVX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was due primarily to higher personnel expenses related to the growth in the number of G&A employees and professional and consulting services.”
From its results filing (SEC filing · Nov 4)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 4, 2026 | +0.3% | -5.7% | not yet |
| Aug 5, 2026 | -1.3% | +5.3% | +6.7% |
| May 6, 2026 | -3.7% | -9.8% | -5.0% |
RSI 53.9, MACD above signal, above both averages. Not scored.
One insider sold $376K across 6 filings in the last 6 months. No open-market buys on record. The newest:
3 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PCVX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
PCVX scores 2 today, which Breakaway calls Below Average. It is #112 of 281 in Biotech by Quality Score, with 4 of 14 chart checks firing. Down 5.7% on Nov 5, a down day for the market: the S&P 500 fell 4%, 86% of stocks fell, and biotech stocks a median 6.3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PCVX scores 2 today, which Breakaway calls Below Average (0 to 5). That is #112 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PCVX's 2.
One insider sold $376K across 6 filings in the last 6 months. No open-market buys on record. The newest is Jim Wassil, EVP, Chief Scientific Ofc, COO, who sold $84K on Sep 4. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.